Rickets - A Pipeline Analysis Report 2018 | Technavio
LONDON--(BUSINESS WIRE)--Jul 9, 2018--Technavio has announced its latest pipeline analysis report on the . The report includes a detailed analysis of the pipeline molecules under investigation within the defined data collection period to treat rickets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20180709005812/en/
Technavio has published a new report on the drug development pipeline for rickets, including a detailed study of the pipeline molecules. (Graphic: Business Wire)
This report presents a detailed analysis of the market, including regulatory framework, drug development strategies, recruitment strategies, and key companies that are expected to play an essential role in the growth of the market in the coming years.
Rickets: market overview
Rickets is a skeletal disorder that occurs because of the deficiency of vitamin D, calcium, or phosphate. These are the essential nutrients for the development of strong and healthy bones. People suffering from rickets usually have weak and soft bones, stunted growth, and in severe cases, skeletal deformities.
According to a senior analyst at Technavio , “Vitamin D facilitates the absorption of calcium and phosphate in the small intestine. Vitamin D deficiency makes it difficult for the human body to maintain sufficient levels of calcium and phosphate. During this situation, the body produces hormones that release calcium and phosphate from the bones, which makes them weak and soft.”
Rickets: segmentation analysis
This market research report segments the rickets market based on therapies employed including monotherapy, RoA (subcutaneous and unknown), therapeutic modalities (enzyme and monoclonal antibody), targets for drugs under development (FGF23 and ENPP1), MoA (ENPP1 and FGF23 inhibitor), and recruitment status (active not recruiting and NA).
In the case of subcutaneous RoA, the delivery of the drug substances is done directly into the layer of the skin below the dermis and the epidermis. In the current pipeline, one molecule is administered subcutaneously.
Enzymes are biological molecules that substantially speed up the rate of virtually all of the chemical reactions that take place within the cell. About 50% of the molecules in the current pipeline are enzymes.
Technavio’s sample reports are free of charge and contain multiple sections of the report such as the market size and forecast, drivers, challenges, trends, and more.
Some of the key topics covered in the report include:
Scope of the Report
Drug Development LandscapeDrugs under development Indications coverage
Drug Development StrategiesTherapies employed RoA Therapeutic modality Geographical coverage
Recruitment StrategiesRecruitment status Gender Age Recruitment volume
Key CompaniesType of players Company overview
Discontinued or Dormant Molecules
is a leading global technology research and advisory company. Their research and analysis focuses on emerging market trends and provides actionable insights to help businesses identify market opportunities and develop effective strategies to optimize their market positions.
With over 500 specialized analysts, Technavio’s report library consists of more than 10,000 reports and counting, covering 800 technologies, spanning across 50 countries. Their client base consists of enterprises of all sizes, including more than 100 Fortune 500 companies. This growing client base relies on Technavio’s comprehensive coverage, extensive research, and actionable market insights to identify opportunities in existing and potential markets and assess their competitive positions within changing market scenarios.
If you are interested in more information, please contact our media team at .
View source version on businesswire.com:https://www.businesswire.com/news/home/20180709005812/en/
CONTACT: Technavio Research
Media & Marketing Executive
US: +1 844 364 1100
UK: +44 203 893 3200
INDUSTRY KEYWORD: HEALTH PHARMACEUTICAL
SOURCE: Technavio Research
Copyright Business Wire 2018.
PUB: 07/09/2018 03:17 PM/DISC: 07/09/2018 03:17 PM